Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes)
ورودیهای بالینی بیمار
حداقل ۴۰ — حداکثر ۶۹ • واحد: years
حداقل ۸۰ — حداکثر ۲۵۰ • واحد: mmHg
حداقل ۲ — حداکثر ۱۲ • واحد: mmol/L
حداقل ۰.۵ — حداکثر ۳.۵ • واحد: mmol/L
حداقل ۱۸ — حداکثر ۶۹ • واحد: years
حداقل ۲۰ — حداکثر ۱۳۰ • واحد: mmol/mol
حداقل ۱۵ — حداکثر ۱۵۰ • واحد: mL/min/1.73m²
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low to Moderate Risk0–2.5
- Moderate Risk2.5–5
- High Risk5–7.5
- High Risk7.5–10
The Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes) calculator is designed for bedside predicting 10-year cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) risk in patients with type 2 diabetes aged under 70 years without prior cardiovascular disease in clinical practice. The resulting score directly.
Clinical Guidelines & Evidence
Predicts 10-year cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) risk in patients with type 2 diabetes aged under 70 years without prior cardiovascular disease.
Clinical Indication
The Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes) is indicated for bedside clinical practice to support Predicts 10-year cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) risk in patients with type 2 diabetes aged under 70 years without prior cardiovascular disease.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines.
Uses Fine and Gray competing risk models with diabetes-specific variables (HbA1c, age at diagnosis, eGFR) added to conventional SCORE2 risk factors, calibrated to four European risk regions
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| sex | string | Yes | Biological sex |
| age | integer | Yes | Age in years(years) |
| smoking | string | Yes | Current smoking status |
| systolic_bp | integer | Yes | Systolic blood pressure(mmHg) |
| total_cholesterol | float | Yes | Total cholesterol(mmol/L) |
| hdl_cholesterol | float | Yes | HDL cholesterol(mmol/L) |
| age_diabetes_diagnosis | integer | Yes | Age at type 2 diabetes diagnosis(years) |
| hba1c | float | Yes | Glycated hemoglobin (HbA1c)(mmol/mol) |
| egfr | float | Yes | Estimated glomerular filtration rate (eGFR)(mL/min/1.73m²) |
| risk_region | string | Yes | Cardiovascular risk region based on country |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2.5 | Low to Moderate Risk | Low to moderate risk (<2.5% for age <50 years) |
| 2.5–5 | Moderate Risk | Moderate risk (2.5-5% for age <50 years or <5% for age 50-69 years) |
| 5–7.5 | High Risk | High risk (5-7.5% for age <50 years or 5-10% for age 50-69 years) |
| 7.5–10 | High Risk | High risk (7.5-10% for age 50-69 years) |
| 10–100 | Very High Risk | Very high risk (≥7.5% for age <50 years or ≥10% for age 50-69 years) |
Evidence-Based References (EBM)
- SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 Jul 21;44(28):2544-2556. doi: 10.1093/eurheartj/ehad260.DOI: 10.1093/eurheartj/ehad260
- Pennells L, Kaptoge S, Østergaard HB, Read SH, Carinci F, Franch-Nadal J, et al. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 Jul 21;44(28):2544-2556.
- Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.DOI: 10.1093/eurheartj/ehab484